Top

Journal of Endocrinological Investigation

Published in:

01-04-2018 | Review

Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index

Authors: R. A. Condorelli, A. E. Calogero, M. Di Mauro, L. M. Mongioi’, R. Cannarella, G. Rosta, S. La Vignera

Published in: Journal of Endocrinological Investigation | Issue 4/2018

Abstract

Background

Insulin resistance is a common feature among women with polycystic ovary syndrome (PCOS), especially in those patients with hyperandrogenism and chronic anovulation. PCOS women are at risk for developing metabolic syndrome, impaired glucose tolerance and type II diabetes mellitus (DM II).

Objective

The aim of this review is to explore the existing knowledge of the interplay between androgen excess, pancreatic β-cell function, non-alcoholic fatty liver disease (NAFLD), intra-abdominal and subcutaneous (SC) abdominal adipocytes in PCOS, providing a better comprehension of the molecular mechanisms of diabetologic interest.

Methods

A comprehensive MEDLINE^® search was performed using relevant key terms for PCOS and DM II.

Results

Insulin-induced hyperandrogenism could impair pancreatic β-cell function, the SC abdominal adipocytes’ lipid storage capacity, leading to intra-abdominal adipocyte hypertrophy and lipotoxicity, which in turn promotes insulin resistance, and could enhance NAFLD. Fetal hyperandrogenism exposure prompts to metabolic disorders. Treatment with flutamide showed to partially reverse insulin resistance.

Conclusions

Metabolic impairment seems not to be dependent only on the total fat mass content and body weight in women with PCOS and might be ascribed to the androgen excess.

Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97(1):28–38CrossRefPubMed

Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE), Androgen Excess and PCOS Society (AES) (2015) American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocr Pract 21(11):1291–1300CrossRefPubMed

Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Updat 20(5):748–758CrossRef

Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE), Androgen Excess and PCOS Society (AES) (2015) American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 2. Endocr Pract 21(12):1415–1426CrossRefPubMed

Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G (2004) Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. JCEM 89(3):1273–1276PubMed

Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK (2016) Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 31:2619–2631CrossRefPubMed

Gambieri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, Pasquali R (2012) Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes 61:2369–2374CrossRef

Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800PubMed

Malin SK, Kirwan JP, Sia CL, Gonzàles F (2015) Pancreatic β-cell dysfunction in polycystic ovary syndrome: role of hyperglycemia-induced nuclear factor-kB activation and systemic inflammation. Am J Physiol Endocrinol Metab 308:E770–E777CrossRefPubMedPubMedCentral

10.

Rosenfield RL, Barnes RB, Ehrmann DA (1994) Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. JCEM 79(6):1686–1692PubMed

11.

Mansour A, Hosseini S, Larijani B, Mohajeri-Tehrani MR (2016) Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome. EXCLI J 15:551–564PubMedPubMedCentral

12.

Navarro G, Xu W, Jacobson DA, Wicksteed B, Allard C, Zhang G, De Gendt K, Kim SH, Wu H, Zhang H, Verhoeven G, Katzenellenbogen JA, Mauvais-Jarvis F (2016) Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metab 23(5):837–851CrossRefPubMedPubMedCentral

13.

Tian S, Lin XH, Xiong YM, Liu ME, Yu TT, Lv M, Zhao W, Xu GF, Ding GL, Xu CM, Jin M, Feng C, Wu YT, Tan YJ, Gao Q, Zhang J, Li C, Ren J, Jin LY, Chen B, Zhu H, Zhang XY, Chen SC, Liu XM, Liu Y, Zhang JY, Wang L, Zhang P, Chen XJ, Jin L, Chen X, Meng YC, Wu DD, Lin H, Yang Q, Zhou CL, Li XZ, Wang YY, Xiang YQ, Liu ZW, Gao L, Chen LT, Pan HJ, Li R, Zhang FH, Xing LF, Zhu YM, Klausen C, Leung PC, Li JX, Sun F, Sheng JZ, Huang HF (2017) Prevalence of prediabetes risk in offspring born to mothers with hyperandrogenism. EBioMedicine 16:275–283CrossRefPubMedPubMedCentral

14.

Makri E, Tziomalos K (2017) Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome. Minerva Endocrinol 42(2):122–131PubMed

15.

Vassilatou E (2014) Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 20:8351–8363CrossRefPubMedPubMedCentral

16.

Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S et al (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 104:12587–12594CrossRefPubMedPubMedCentral

17.

Jornayvaz FR, Samuel VT, Shulman GI (2010) The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and non-alcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr 30:273–290CrossRefPubMedPubMedCentral

18.

Baranova A, Tran TP, Afendy A, Wang L, Shamsaddini A, Mehta R et al (2013) Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 11:133CrossRefPubMedPubMedCentral

19.

Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E et al (2016) Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 31:1347–1353CrossRefPubMed

20.

Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR (1997) Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 138:3779–3786CrossRefPubMed

21.

Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN (2010) Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. JCEM 95:3332–3341PubMed

22.

Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N et al (2012) Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. JCEM 97:3709–3716PubMed

23.

Abruzzese GA, Heber MF, Ferreira SR, Velez LM, Reynoso R, Pignataro OP, Motta AB (2016) Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism. J Endocrinol 230(1):67–79CrossRefPubMed

24.

Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. JCEM 65:499–507PubMed

25.

Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A et al (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 39:351–355CrossRef

26.

Dimitriadis GK, Kyrou I, Randeva HS (2016) Polycystic ovary syndrome as a proinflammatory state: the role of adipokines. Curr Pharm Des 22(36):5535–5546CrossRefPubMed

27.

Mannerås-Holm L, Leonhardt H, Kullberg J et al (2011) Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. JCEM 96:E304–E311PubMed

28.

McLaughlin T, Lamendola C, Liu A, Abbasi F (2011) Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. JCEM 96:E1756–E1760PubMedPubMedCentral

29.

Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, Thomas AM, Grogan TR, Haykal R, Schooler TA, Okeya BL, Abbott DH, Chazenbalk GD (2016) Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. JCEM 101(11):4178–4188PubMedPubMedCentral

30.

Li H, Xu X, Wang X, Liao X, Li L, Yang G, Gao L (2016) Free androgen index and Irisin in polycystic ovary syndrome. J Endocrinol Invest 39(5):549–556CrossRefPubMed

31.

Mario FM, Graff SK, Spritzer PM (2017) Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study. J Endocrinol Invest 40(4):377–384CrossRefPubMed

32.

Moghetti P, Tosi F, Castello R et al (1996) The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. JCEM 81:952–960PubMed

33.

Wallace IR, McKinley MC, Bell PM, Hunter SJ (2013) Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf) 78:321–329CrossRef

34.

Le TN, Nestler JE, Strauss JF 3rd, Wickam EP 3rd (2012) Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab 23:32–40CrossRefPubMed

Title: Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index
Authors: R. A. Condorelli
A. E. Calogero
M. Di Mauro
L. M. Mongioi’
R. Cannarella
G. Rosta
S. La Vignera
Publication date: 01-04-2018
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 4/2018
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-017-0762-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

Effects of tetramethylpyrazine phosphate on pancreatic islet microcirculation in SD rats

Interaction between gender and uric acid on hemoglobin A1c in community-dwelling persons

The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study

Recombinant growth hormone therapy for prepubertal children with idiopathic short stature in Korea: a phase III randomized trial

Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism

Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials